Piramal Pharma Q1FY27 Revenue Up 17% to ₹2,270 Cr, EBITDA Soars 72%
Piramal Pharma Limited reported Q1 FY27 revenue of ₹2,270 crore, a 17% increase YoY. EBITDA surged 72% to ₹285 crore, with margins expanding to 12.5%. CDMO, CHG, and PCH businesses all showed robust growth. The company will host an earnings call on July 30, 2026.
The results show substantial financial growth and operational improvements across all business verticals, indicating a positive impact on the company's performance and market position.
The company reported strong year-on-year growth in revenue and a significant increase in EBITDA and EBITDA margins across all its business segments. The commentary from the Chairperson also indicates positive momentum and future outlook.
Piramal Pharma Limited (PPL) announced its standalone and consolidated financial results for the First Quarter (Q1) ended 30th June 2026. The company reported a healthy 17% year-on-year revenue growth, reaching ₹2,270 crore. This growth was broad-based across all three business segments: CDMO, CHG, and PCH.
The Contract Development and Manufacturing Organization (CDMO) business saw a 19% increase in revenue to ₹1,187 crore, driven by strong order inflows, enhanced commercial capabilities, and improved execution. The company also highlighted progress in its Antibody-Drug Conjugate (ADC) capabilities, with the inauguration of a commercial-scale payload-linker suite at Riverview, US, and ongoing sterile injectables capacity expansion at Lexington, US. A strategic partnership with Ajinomoto Bio-Pharma Services for next-gen conjugation technology was also noted.
The Complex Hospital Generics (CHG) business reported a 17% revenue increase to ₹743 crore. PPL maintained its leadership in the US Sevoflurane market with a 48% value share and continued to hold the #1 position in the US intrathecal Baclofen market. Integration of Kenalog® is progressing, with supplies expected to commence in Q2FY27.
The Consumer Healthcare (PCH) business achieved 15% revenue growth, amounting to ₹347 crore. This was primarily driven by a 23% year-on-year growth in Power Brands and a 40% growth in e-commerce sales. PPL continues to invest in brand promotion and expand its multi-channel distribution network.
Consolidated EBITDA surged by 72% to ₹285 crore, with the EBITDA margin expanding by approximately 400 basis points to 12.5%, reflecting improved operating leverage and execution. Profit After Tax (PAT) before exceptional items was ₹(69) crore, a 32% improvement compared to Q1FY26. The company's Sellersville facility in the US successfully concluded its inspection by the US FDA, maintaining a Zero OAI status.
Piramal Pharma Limited will host an earnings conference call on 30th July 2026, from 9:30 AM to 10:15 AM IST, to discuss the Q1 FY2027 results.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.